http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

吗氯贝胺缓释片多剂量口服后在人体的药代动力学研究

胡道德*, 毛丹卓, 裴元英   

  1. 1.上海交通大学附属第一人民医院药剂科, 上海 200080;
    2.复旦大学药学院药剂学教研室, 上海 200032
  • 收稿日期:2004-07-14 修回日期:2004-11-10 出版日期:2004-12-15 发布日期:2004-12-15
  • 通讯作者: 胡道德*

Pharmacokinetics of Moclobemide Sustained Release Tablets after Multiple Oral Dose Administration in Healthy Volunteers

HU Dao-de*, MAO Dan-zhuo, PEI Yuan-ying   

  1. 1.Department of Pharmacy, Affiliated First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China;
    2.Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China
  • Received:2004-07-14 Revised:2004-11-10 Online:2004-12-15 Published:2004-12-15
  • Contact: HU Dao-de*

摘要: 目的 研究中国健康男性志愿者多剂量口服吗氯贝胺缓释片的药代动力学特征. 方法 十二名健康志愿者口服吗氯贝胺缓释片, 每日一次, 每次一片,连续服五天. 采用反相高效液相色谱法测定人血浆中吗氯贝胺含量. 应用3p97程序拟合药动学参数. 结果 吗氯贝胺血药浓度-时间曲线符合一室模型, 主要稳态药动学参数Cmax(1 950±156) μg·L-1, Tmax(6.00±1.55) h, T1/2(kel) (3.14±0.12) h, AUCss0-24 (22836±1842) μg·h·L-1, MRT(7.68±0.36) h, CL/F(s) (20.2±2.1) L·h-1, V/F(c)(91.4±9.4) L. 试验期间, 受试者未出现明显的不良反应. 结论 吗氯贝胺缓释片具有缓释作用和良好的耐受性, 其结果可为临床应用提供参考.

关键词: 吗氯贝胺缓释片, 吗氯贝胺缓释片, 吗氯贝胺缓释片, 高效液相色谱法, 高效液相色谱法, 高效液相色谱法, 药代动力学, 药代动力学, 药代动力学, 多剂量, 多剂量, 多剂量

Abstract: Aim To investigate the pharmacokinetic characteristics of moclobemide sustained release tablets after multiple oral dose administration in healthy Chinese volunteers. Methods Moclobemide sustained release tablets were given as a multiple oral dose regimen of 300 mg once daily for five consecutive days to 12 healthy volunteers. The concentrations of moclobemide in plasma were determined by reversed-phase high performance liquid chromatography. The partial pharmacokinetic parameters were calculated using 3p97 pharmacokinetic program. Results The concentration-time profile fitted an one-compartment model best. The steady-state pharmacokinetic parameters of moclobemide sustained release tablets after multiple oral doses were as follows: Cmax was (1 950±156)μg·L-1, Tmax was (6.00±1.55) h, T1/2(kel) was (3.14±0.12) h, AUCss0-24 was (22836±1842) μg·h·L-1, MRT was (7.68±0.36) h, CL/F(s) was (20.2±2.1) L·h-1, and V/F(c) was (91.4±9.4) L, respectively. No marked adverse events were noted during this study. Conclusion The formulation has a sustained-release effect and good tolerance in the healthy volunteers, which provides useful information for clinical practice.

Key words: moclobemide sustained release tablets, moclobemide sustained release tablets, high performance liquid chromatography, high performance liquid chromatography, pharmacokinetics, pharmacokinetics, multiple dose, multiple dose

中图分类号: 

Supporting: *Corresponding author. Tel.: 86-21-63240090-4038, fax: 86-21-63240417